📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-14 15:05
510 analysed today
510
Today
133,399
All-time analysed
40,108
Positive
6,279
Negative
79,197
Neutral
7,747
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
24 announcements match the current filters (relevance ≥ 5).
18% YoY Revenue Growth to Rs 248 Cr in Q1 FY27; Plant 6 Commercialization by H1
Windlas Biotech reported its highest-ever quarterly revenue of Rs 248 crore in Q1 FY27, marking 14 consecutive quarters of growth. The CDMO segment was the primary driver, growing 29% YoY to Rs 207 crore, while the Trade Generics segment (Rs 30 crore) was impacted by the discontinuation of codeine-based products. Adjusted PAT (excluding Rs 7.2 crore non-cash ESOP expenses) grew 37% YoY to Rs 25 crore. The company is on track to commercialize Plant 6 by the end of H1 FY27, which is expected to add approximately Rs 3 crore in quarterly depreciation starting Q3.
Confidence: HIGH
What changedThe company achieved record quarterly revenue and provided a firm timeline for the commercialization of its next major capacity expansion (Plant 6).
Why it mattersThe strong performance in CDMO and Exports offsets the regulatory impact on the Trade Generics business, proving the resilience of the diversified business model and setting the stage for further scale via Plant 6.
Q1 FY27 Revenue: Rs 248 CrCDMO Revenue Growth: 29% YoYAdjusted PAT (Ex-ESOP): Rs 25 CrBuyback Value: Rs 47 CrIncremental Quarterly Depreciation (Plant 6): Rs 3 CrRevenue vs TTM Revenue: ~26%
📅 Short termThe stock may react positively to the record revenue and the 37% growth in adjusted PAT, alongside the clarity on the buyback completion.
📈 Long termThe structural shift toward injectables and the expansion of the export vertical provide a pathway for sustained 18-20% growth as Plant 6 ramps up.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High client concentration in the CDMO segment
- Volatility in API prices impacting margins
- Regulatory risks associated with product portfolio changes
Key Highlights
Achieved highest-ever quarterly revenue of Rs 248 crore, an 18% YoY increase.
CDMO vertical grew 29% YoY to Rs 207 crore, now representing ~83% of total revenue.
Exports vertical recorded 79% YoY growth to Rs 11 crore, targeting semi-regulated markets.
Plant 6 commercialization scheduled for the end of H1 FY27 (September 2026).
Completed a Rs 47 crore buyback and declared a dividend of Rs 13 crore (Rs 6.30 per share).
👀 What to Watch
Watch for the successful commissioning of Plant 6 by September 2026 and its subsequent impact on margins as depreciation kicks in. Monitor the recovery in the Trade Generics segment as the company launches new products to replace the discontinued codeine portfolio.
18% Revenue Growth to ₹248 Cr in Q1 FY27; CDMO Vertical Surges 29% YoY
Windlas Biotech reported its 14th consecutive quarter of record revenue at ₹248 Cr for Q1 FY27, driven by a robust 29% growth in its core CDMO segment. Adjusted PAT (excluding non-cash ESOP expenses) grew 37% YoY to ₹25 Cr, though reported PAT stood at ₹18 Cr due to a ₹7.16 Cr ESOP charge. The company completed a ₹47 Cr share buyback and is on track to commercialize its new Plant-6 in H1 FY27. While the Trade Generics segment declined 32% due to product portfolio shifts, the Exports vertical showed strong momentum with 79% growth.
Confidence: HIGH
What changedWindlas achieved its highest-ever quarterly revenue while successfully navigating the discontinuation of codeine-based products in its Trade Generics segment.
Why it mattersThe strong performance in the CDMO vertical (84% of revenue) and the upcoming capacity expansion at Plant-6 indicate a solid growth trajectory and operational leverage despite industry-wide volume pressures.
Q1 FY27 Revenue: ₹248 CrCDMO Revenue Growth: 29% YoYAdjusted PAT: ₹25 CrNon-cash ESOP Expense: ₹7.16 CrBuyback vs Market Cap: ~2.37%Q1 Revenue vs TTM Revenue: ~27.4%
📅 Short termThe market is likely to react positively to the record revenue and strong CDMO growth, though the reported PAT impact from ESOPs may be a minor talking point.
📈 Long termThe structural shift toward higher-margin injectables and the commercialization of new facilities (Plant-6) support the company's long-term growth target of 18-20%.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- 32% decline in Trade Generics & Institutional vertical
- High client concentration in the CDMO segment
- Impact of non-cash ESOP expenses on reported profitability
Key Highlights
Revenue from operations reached a record ₹248 Cr, up 18% YoY from ₹210 Cr.
Generic Formulations CDMO vertical grew 29% YoY to ₹207 Cr, now contributing 84% of total revenue.
Adjusted EBITDA grew 26% YoY to ₹34 Cr with margins at 13.6%, excluding ₹7.16 Cr ESOP expenses.
Exports vertical grew 79% YoY to ₹11 Cr, reflecting successful penetration in semi-regulated markets.
Completed a ₹47 Cr share buyback without promoter participation and paid ₹13 Cr in dividends.
👀 What to Watch
Watch for the successful commercialization of Plant-6 in H1 FY27 and the ramp-up of the new injectables facility, which are key to sustaining the 18-20% growth guidance.
18% Revenue Growth in Q1 FY27; CDMO Vertical Up 29% YoY to Rs 207 Cr
Windlas Biotech reported its 14th consecutive quarter of record revenue at Rs 248 Cr for Q1 FY27, an 18% YoY increase. While reported PAT remained flat at Rs 18 Cr due to a non-cash ESOP charge of Rs 7.16 Cr, adjusted PAT (excluding ESOP) grew 37% YoY to Rs 25 Cr. The core CDMO business showed strong momentum with 29% growth, offsetting a 32% decline in Trade Generics caused by the discontinuation of codeine-based products. The company maintains a strong liquidity position of Rs 251 Cr and is on track to commercialize Plant-6 in H1 FY27.
Confidence: HIGH
What changedThe company transitioned into Q1 FY27 with strong CDMO growth but faced a temporary revenue hit in Trade Generics due to regulatory-led product discontinuations, while also accounting for a significant one-time ESOP expense.
Why it mattersThe results validate the scalability of the CDMO model (84% of revenue) and the company's ability to maintain a net-debt-free balance sheet (Rs 251 Cr liquidity) while funding capacity expansions like Plant-6.
Q1 FY27 Revenue: Rs 248 CrAdjusted PAT Growth (YoY): 37%CDMO Revenue Growth (YoY): 29%Buyback Value: Rs 47 CrNet Liquidity: Rs 251 CrPlant-6 Commercialization: H1 FY27
📅 Short termThe market is likely to react positively to the record revenue and strong CDMO growth, though the flat reported PAT (due to ESOPs) may require investor education on adjusted metrics.
📈 Long termStructural growth remains intact driven by the upcoming Plant-6 injectable facility and a shift toward complex generics, supported by a high ROCE of 32% (FY26 adjusted).
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High client concentration in the CDMO segment
- Revenue volatility in Trade Generics due to product discontinuations
- Execution risk in the ramp-up of the new injectable facility
Key Highlights
Achieved record quarterly revenue of Rs 248 Cr, marking 18% YoY growth and the 14th consecutive record quarter.
Generic Formulations CDMO vertical, the largest segment, grew 29% YoY to Rs 207 Cr.
Adjusted EBITDA (excluding Rs 7.16 Cr ESOP expense) grew 26% YoY to Rs 34 Cr with a 13.6% margin.
Exports vertical recorded 79% YoY growth to Rs 11 Cr, expanding penetration in semi-regulated markets.
Completed a Rs 47 Cr buyback (promoters did not participate) and declared a Rs 13 Cr dividend for FY26.
👀 What to Watch
Watch for the successful commercialization of Plant-6 in H1 FY27, which is expected to drive the next leg of growth through injectables. Additionally, monitor the recovery in the Trade Generics vertical as the company replaces discontinued codeine-based products with new launches.
Windlas Biotech Q1 Revenue Grows 18% YoY to ₹248 Cr; PAT Stagnant at ₹17.7 Cr
Windlas Biotech reported a strong 18.1% YoY revenue growth for Q1 FY27, reaching ₹248.1 cr, up from ₹210.1 cr in the previous year. However, Net Profit (PAT) remained flat at ₹17.65 cr compared to ₹17.67 cr in Q1 FY26, as margins were pressured by a 34.4% increase in raw material costs. The company completed a ₹47 cr buyback of 4.7 lakh shares at ₹1,000 per share during the period, representing approximately 8.1% of its net worth. Following the dissolution of its US subsidiary, the company has transitioned to standalone-only financial reporting.
Confidence: HIGH
What changedWindlas reported its Q1 FY27 results showing top-line growth but bottom-line stagnation, completed a ₹47 cr share buyback, and simplified its corporate structure by dissolving its non-operating US subsidiary.
Why it mattersThe results demonstrate healthy demand in the CDMO and Trade Generics segments but highlight significant input cost inflation. The buyback indicates management's confidence in the company's valuation and efficient capital allocation.
Revenue (Q1 FY27): ₹248.1 crPAT (Q1 FY27): ₹17.65 crBuyback Value: ₹47 crBuyback vs Net Worth: ~8.1%Material Cost Increase (YoY): 34.4%
📅 Short termThe stock may see neutral to slightly cautious movement as the market weighs strong revenue growth against flat profitability and margin compression.
📈 Long termStructural growth remains tied to the 18-20% guidance and the successful scale-up of the injectables segment and trade generics portfolio.
⚠ Risk flags
- Margin compression due to rising raw material costs
- High client concentration in the CDMO segment
- Significant increase in employee benefit expenses
Key Highlights
Revenue from operations increased 18.1% YoY to ₹248.1 cr from ₹210.1 cr.
Net Profit (PAT) remained flat at ₹17.65 cr, impacted by higher material costs of ₹168.7 cr vs ₹125.5 cr YoY.
Completed buyback of 470,000 equity shares at ₹1,000 per share, totaling ₹47 cr.
Employee benefit expenses rose 37.8% YoY to ₹44.4 cr, including ₹7.16 cr in share-based payment expenses.
Paid a dividend of ₹6.30 per share on July 31, 2026, totaling ₹13.0 cr.
👀 What to Watch
Investors should monitor the ramp-up of the new injectables facility and export growth to see if they can offset the current margin pressure from rising raw material and employee costs. The impact of the reduced share capital on EPS should be observed in the coming quarters.
₹6.30 Final Dividend: Windlas Biotech Sets July 16 as Record Date for 25th AGM
Windlas Biotech has scheduled its 25th Annual General Meeting (AGM) for July 23, 2026, and fixed July 16, 2026, as the record date for a final dividend of ₹6.30 per share. This dividend represents a 126% payout on the face value of ₹5 and approximately 19.9% of the TTM EPS of ₹31.61. The company is also seeking shareholder approval for the re-appointment of Managing Director Hitesh Windlass and the appointment of Dr. Tarashree Singhal as an Independent Director for a five-year term. Financially, the company remains stable with a low debt-to-equity ratio of 0.06 and TTM revenue of ₹904 Cr.
Confidence: HIGH
What changedThe company has formalized the schedule for its 25th AGM and confirmed the record date for its ₹6.30 final dividend.
Why it mattersThe announcement confirms a cash return to shareholders (approx. 0.73% yield at current price) and ensures governance continuity through director appointments.
Final Dividend: ₹6.30 per shareDividend Payout vs TTM EPS: ~19.9%Dividend Yield: ~0.73%Record Date: July 16, 2026AGM Date: July 23, 2026
📅 Short termThe stock may see mild interest leading up to the July 16 record date as investors seek to qualify for the dividend payout.
📈 Long termLimited structural impact from this routine filing, though the appointment of a new Independent Director supports long-term governance.
Key Highlights
Final dividend of ₹6.30 per equity share (126% of face value) proposed for FY 2025-26.
Record date for dividend entitlement and AGM voting fixed as July 16, 2026.
Appointment of Dr. Tarashree Singhal as Independent Director for a 5-year term from May 5, 2026, to May 4, 2031.
Ratification of Cost Auditor remuneration at ₹60,000 for the financial year ending March 31, 2027.
Remote e-voting period scheduled from July 20, 2026, to July 22, 2026.
👀 What to Watch
Investors should ensure their bank details are updated with depositories by the July 16 record date to receive the dividend, and monitor the AGM for management commentary on the new injectable facility's progress.
Rs 6.30 Dividend Declared; Windlas Biotech to Hold 25th AGM on July 23, 2026
Windlas Biotech has scheduled its 25th Annual General Meeting (AGM) for July 23, 2026, primarily to approve a final dividend of Rs 6.30 per equity share for FY26. The company has fixed July 16, 2026, as the record date for determining dividend eligibility. Other key agenda items include the appointment of Dr. Tarashree Singhal as an Independent Director for a five-year term and the re-appointment of Managing Director Mr. Hitesh Windlass. The proposed dividend represents a 126% payout on the face value of Rs 5.
Confidence: HIGH
What changedThe company has formalized the schedule for its 25th AGM and confirmed the specific dividend amount and record date for FY26.
Why it mattersThe dividend provides a tangible cash return to shareholders, while the appointment of a new independent director is a key step in maintaining corporate governance standards.
Final Dividend: Rs 6.30 per shareDividend Yield (at Rs 860.8): 0.73%Record Date: July 16, 2026AGM Date: July 23, 2026Cost Auditor Remuneration: Rs 60,000
📅 Short termThe stock may witness minor positive sentiment leading up to the record date of July 16 as investors seek to qualify for the dividend.
📈 Long termRoutine corporate action; the long-term trajectory depends on the company's ability to achieve its 18-20% growth target through its new injectable facility and trade generics expansion.
Key Highlights
Proposed final dividend of Rs 6.30 per equity share for the financial year 2025-26
Record date for dividend entitlement and e-voting eligibility fixed as July 16, 2026
Appointment of Dr. Tarashree Singhal as an Independent Director for a 5-year term starting May 5, 2026
Ratification of Cost Auditor remuneration at Rs 60,000 for the financial year ending March 31, 2027
E-voting period scheduled from July 20, 2026 (9:00 AM) to July 22, 2026 (5:00 PM)
👀 What to Watch
Investors should ensure their bank details are updated with depositories before the July 16 record date to receive the dividend. Watch for the AGM proceedings for updates on the injectable facility ramp-up and export strategy.
₹6.30 Dividend: Windlas Biotech Sets July 16, 2026, as Record Date
Windlas Biotech has announced July 16, 2026, as the record date for a final dividend of ₹6.30 per equity share for FY2025-26. This payout represents 126% of the ₹5 face value and is subject to shareholder approval at the upcoming 25th AGM on July 23, 2026. Based on the TTM EPS of ₹31.61, the dividend represents a payout ratio of approximately 19.9%. The current dividend yield stands at approximately 0.73% based on the last closing price of ₹860.8.
Confidence: HIGH
What changedThe company has finalized the administrative timeline (record date and AGM date) for its previously recommended FY26 dividend.
Why it mattersThe dividend confirms the company's consistent cash-flow generation and commitment to shareholder returns while maintaining a low Debt/Equity ratio of 0.06.
Dividend per share: ₹6.30Face Value: ₹5Record Date: 16-Jul-2026Dividend Yield: ~0.73%Payout Ratio (vs TTM EPS): ~19.9%
📅 Short termThe stock price may adjust by the dividend amount on the ex-dividend date; neutral to slightly positive sentiment is expected leading up to the record date.
📈 Long termLimited structural impact from the dividend; long-term value depends on achieving the 18-20% growth target and scaling the Trade Generics portfolio.
Key Highlights
Final dividend of ₹6.30 per equity share recommended for FY2025-26
Record date for dividend eligibility fixed as July 16, 2026
25th Annual General Meeting (AGM) scheduled for July 23, 2026
Dividend represents 126% of the face value of ₹5 per share
Payout ratio is approximately 19.9% relative to TTM EPS of ₹31.61
👀 What to Watch
Investors seeking the dividend must hold the stock prior to the ex-dividend date (typically one business day before the record date). Monitor the AGM on July 23 for updates on the injectable facility ramp-up and export growth targets.
ICRA Upgrades Short-Term Rating to [ICRA]A1+; Reaffirms Long-Term [ICRA]A+ (Stable)
ICRA Limited has upgraded Windlas Biotech's short-term credit rating for its working capital facilities to [ICRA]A1+ from [ICRA]A+. The long-term rating for the same facilities, totaling Rs 84.90 crore, has been reaffirmed at [ICRA]A+ with a Stable outlook. This rating action covers facilities across HSBC, HDFC Bank, and IndusInd Bank. Given the company's very low debt-to-equity ratio of 0.06, this upgrade further solidifies its strong credit profile and liquidity position.
Confidence: HIGH
What changedICRA has upgraded the company's short-term credit rating while maintaining the long-term rating at A+ (Stable).
Why it mattersA higher credit rating typically allows a company to negotiate better interest rates with lenders and reflects a robust liquidity position, which is crucial for a CDMO player managing working capital for large clients.
Total Rated Facilities: Rs 84.90 CrRated Facilities vs TTM Revenue: ~9.4%Current Debt-to-Equity: 0.06New Short-term Rating: [ICRA]A1+Long-term Rating: [ICRA]A+ (Stable)
📅 Short termThe news is fundamentally positive and confirms financial stability, though it is unlikely to cause a significant short-term price movement given the company's already low debt levels.
📈 Long termThe upgrade supports the company's long-term growth strategy in the injectables and trade generics segments by ensuring access to efficient capital markets and banking facilities.
⚠ Risk flags
- High client concentration in the CDMO segment
- Potential elongation of the debtor cycle impacting working capital
Key Highlights
Short-term rating for working capital facilities upgraded to [ICRA]A1+ from [ICRA]A+
Long-term rating reaffirmed at [ICRA]A+ with a Stable outlook
Total bank facilities rated by ICRA amount to Rs 84.90 crore
Rated facilities are distributed among HSBC (Rs 40.10 Cr), HDFC Bank (Rs 23.30 Cr), and IndusInd Bank (Rs 21.50 Cr)
The total rated amount represents approximately 9.4% of the company's TTM revenue of Rs 904 crore
👀 What to Watch
Investors should monitor if this credit upgrade translates into lower interest rates on working capital borrowings, which would marginally benefit the OPM (currently 11.6%) as the company scales its new injectables facility.
Windlas Biotech FY26 Revenue Hits Record ₹904 Cr, Up 19%; Proposes ₹6.3 Dividend
Windlas Biotech Limited reported a strong financial performance for FY26, with annual revenue crossing the ₹900 crore milestone for the first time. The company achieved its highest post-listing EPS of ₹31.60 while maintaining capital efficiency with ROCE and ROE consistently above 25%. Growth was primarily driven by the CDMO vertical (up 20%) and the Export vertical (up 40%), supported by a robust net liquidity position of ₹251 crores.
Key Highlights
Annual revenue grew 19% YoY to ₹904 crores, marking 13 consecutive quarters of record revenue.
Adjusted EBITDA stood at ₹121 crores (13.4% margin) and PAT at ₹83 crores (9.2% margin) for FY26.
Generated ₹105 crores in net operating cash flow and completed a ₹47 crore buyback without promoter participation.
Plant 6 has achieved mechanical completion with commercialization expected in H1 FY27.
Board proposed a final dividend of ₹6.3 per share, totaling ₹13 crores for the fiscal year.
👀 What to Watch
Investors should focus on the upcoming commercialization of Plant 6 and the scaling of the injectable and export segments, which are expected to drive future growth. The company's strong cash position and high return ratios (25%+) indicate a healthy balance sheet and efficient capital allocation.
Windlas Biotech Reports Record FY26 Revenue of ₹904 Cr, Adjusted PAT Up 31% YoY
Windlas Biotech achieved its 13th consecutive quarter of record revenue, closing FY26 with a total income of ₹904 crore, representing a 19% YoY growth. The company's core CDMO vertical grew by 20% to ₹664 crore, while the export segment surged by 40% to ₹46 crore. Profitability improved significantly with adjusted PAT rising 31% to ₹83 crore and maintaining high return ratios with an ROE of 29% and ROCE of 32%. The company remains net debt-free with a strong liquidity position of ₹251 crore and has proposed a dividend of ₹6.30 per share.
Key Highlights
FY26 Revenue grew 19% YoY to ₹904 Cr; Q4 revenue up 18% YoY to ₹238 Cr
Adjusted PAT for FY26 increased 31% YoY to ₹83 Cr with an EPS of ₹31.60
CDMO vertical, the largest contributor (73%), grew 20% YoY to ₹664 Cr in FY26
Strong balance sheet with ₹251 Cr net liquidity and ₹105 Cr cash generated from operations
Plant-6 achieved mechanical completion with commercialization on track for H1 FY27
👀 What to Watch
Investors should take note of the company's consistent double-digit growth and superior return ratios (ROCE 32%) in the CDMO space. The upcoming commercialization of Plant-6 and expansion into injectables serve as key catalysts for sustained growth in FY27.
Windlas Biotech FY26 Revenue Hits Record ₹904 Cr, Up 19%; Proposes ₹6.30 Dividend
Windlas Biotech reported a strong FY26 with record revenues of ₹904 crore, driven by 20% growth in its core CDMO segment. Adjusted PAT (excluding non-cash ESOP charges) grew significantly by 31% to ₹83 crore, reflecting improved operational efficiency and a 13.4% adjusted EBITDA margin. The company remains net debt-free with a strong liquidity position of ₹251 crore and has proposed a dividend of ₹6.30 per share. Additionally, the completion of a ₹47 crore buyback and the upcoming commercialization of Plant-6 in H1 FY27 signal continued growth momentum.
Key Highlights
Achieved highest-ever annual revenue of ₹904 Cr, marking 13 consecutive quarters of record revenue growth.
Adjusted EBITDA (excluding ESOP costs) grew 26% YoY to ₹121 Cr with an improved margin of 13.4%.
Core CDMO vertical revenue increased by 20% to ₹664 Cr, while the Export segment grew by 40% to ₹46 Cr.
Maintained robust capital efficiency with an ROE of 29% and ROCE of 32% for FY26.
Plant-6 mechanical completion achieved; commercialization on track for H1 FY27 to drive future capacity.
👀 What to Watch
Investors should take note of the company's strong cash flow generation and high return ratios which support the proposed dividend and recent buyback. The upcoming operationalization of Plant-6 and growth in the high-margin Export segment are key catalysts for future valuation re-rating.
Windlas Biotech Recommends Rs 6.30 Dividend and Approves FY26 Audited Financial Results
Windlas Biotech has approved its audited standalone and consolidated financial results for the quarter and fiscal year ended March 31, 2026. The Board of Directors recommended a final dividend of Rs. 6.30 per equity share, which is 126% of the face value of Rs. 5. The statutory auditors issued an unmodified opinion on the financial statements, indicating no major accounting discrepancies. The company's US subsidiary, Windlas Inc, contributed a small net profit of Rs. 0.21 million for the full year.
Key Highlights
Recommended a final dividend of Rs. 6.30 per equity share (126% of face value)
Approved audited standalone and consolidated financial results for the fiscal year ended March 31, 2026
Statutory auditors J C Bhalla & Co issued an unmodified audit report for the period
US subsidiary Windlas Inc reported a total annual net profit of Rs. 0.21 million
Dividend payout is subject to approval by shareholders at the upcoming Annual General Meeting
👀 What to Watch
Investors should view the dividend recommendation as a positive sign of cash flow stability. It is advised to review the detailed profit and loss statement for year-on-year growth trends once the full tables are released.
Windlas Biotech Completes Buyback of 4.7 Lakh Shares at ₹1,000 Per Share
Windlas Biotech has successfully concluded its share buyback program, extinguishing 4,70,000 equity shares at a price of ₹1,000 per share. The buyback was conducted via the tender offer route between April 30 and May 07, 2026. This corporate action has reduced the total paid-up equity shares from 2,11,06,229 to 2,06,36,229. As a result of the share count reduction, the promoter group's shareholding has increased from 61.90% to 63.31%.
Key Highlights
Extinguished 4,70,000 fully paid-up equity shares of face value ₹5 each
Buyback price executed at ₹1,000 per share via the tender offer route
Total paid-up equity capital reduced from ₹10.55 crore to ₹10.32 crore
Promoter and promoter group stake increased from 61.90% to 63.31%
The share extinguishment was completed and confirmed by NSDL on May 16, 2026
👀 What to Watch
The reduction in the total share base is expected to be EPS-accretive for the remaining shareholders. Investors should note the increase in promoter skin-in-the-game as a positive signal regarding the company's long-term value.
Windlas Biotech to Buyback 4.7 Lakh Shares at ₹1,000/Share via Tender Offer
Windlas Biotech has issued a Letter of Offer for the buyback of 4,70,000 equity shares at a price of ₹1,000 per share, totaling ₹47 crore. This represents 2.23% of the company's total equity and 9.80% of its paid-up capital and free reserves as of March 2025. The buyback is being conducted through the tender offer route for shareholders holding shares as of the record date, April 24, 2026. The tendering window is scheduled to open on April 30, 2026, and close on May 07, 2026.
Key Highlights
Buyback of 4,70,000 shares at a fixed price of ₹1,000 per share via tender route
Total buyback size is ₹47 crore, representing 9.80% of total paid-up capital and free reserves
Entitlement ratio is approximately 1 equity share for every 18 shares held as of the record date
Buyback window opens on April 30, 2026, and closes on May 07, 2026
The offer covers 2.23% of the total existing paid-up equity share capital of the company
👀 What to Watch
Eligible shareholders as of the April 24 record date should consider tendering their shares to capitalize on the ₹1,000 buyback price. Ensure that tender forms are submitted through brokers before the May 7 deadline.
Windlas Biotech Approves ₹47 Cr Buyback at ₹1,000/Share; Record Date April 24, 2026
Windlas Biotech's Board has approved a buyback of up to 4,70,000 equity shares at a price of ₹1,000 per share, representing 2.23% of the total paid-up capital. The total buyback size is capped at ₹47 crore, which constitutes 9.80% of the company's aggregate paid-up capital and free reserves. The buyback will be executed through the tender offer route, and the record date for eligibility is fixed as April 24, 2026. Notably, the promoters and promoter group have decided not to participate in this buyback, which likely increases the acceptance ratio for public shareholders.
Key Highlights
Buyback price of ₹1,000 per share is likely at a significant premium to the current market price.
Total buyback size of ₹47 crore represents 9.80% of the company's total net worth as of March 31, 2025.
Record date for determining eligible shareholders is set for April 24, 2026.
Promoters holding 61.90% of the company will not participate, enhancing the potential acceptance ratio for retail investors.
15% of the buyback (70,500 shares) is reserved for small shareholders as per SEBI regulations.
👀 What to Watch
Investors looking to benefit from the buyback premium should ensure they hold the shares in their demat account by the record date of April 24, 2026. The non-participation of promoters makes this an attractive opportunity for retail shareholders due to a potentially higher acceptance ratio.
Windlas Biotech Approves ₹47 Crore Buyback at ₹1,000 Per Share via Tender Offer
Windlas Biotech's board has approved a buyback of up to 4,70,000 equity shares, representing 2.23% of the total paid-up capital. The buyback is priced at ₹1,000 per share, involving a total outlay of ₹47 crore, which is approximately 9.8% of the company's free reserves. Significantly, the promoters and promoter group have opted not to participate in this offer, which is likely to result in a higher acceptance ratio for public shareholders. The record date to determine eligibility has been set for April 24, 2026.
Key Highlights
Buyback of 4,70,000 shares at a price of ₹1,000 per share via the Tender Offer route.
Total buyback size is ₹47 crore, representing 9.8% of the aggregate paid-up capital and free reserves.
Promoters and Promoter Group (holding 61.90% stake) will not participate in the buyback.
Record date for eligibility is fixed as April 24, 2026.
15% of the buyback is reserved for small shareholders as per SEBI regulations.
👀 What to Watch
Eligible shareholders should consider tendering their shares to capitalize on the premium buyback price. The non-participation of promoters makes this particularly attractive for retail investors due to the potential for a high acceptance ratio.
Windlas Biotech Shareholders Approve Re-appointment of 3 Directors with 99.99% Majority
Windlas Biotech Limited has announced the results of its postal ballot, where shareholders overwhelmingly approved the re-appointment of three key board members. Mr. Ashok Kumar Windlass was re-appointed as Whole-time Director, while Mr. Vivek Dhariwal and Mr. Gaurav Gulati were re-appointed as Independent Directors. Out of 15,320,885 total valid votes cast, 15,320,883 votes (99.99%) were in favor of the resolutions. This ensures leadership continuity for the company starting May 2026.
Key Highlights
Re-appointment of Ashok Kumar Windlass as Whole-time Director approved with 15,320,883 votes in favor.
Independent Directors Vivek Dhariwal and Gaurav Gulati re-appointed effective May 6, 2026.
High shareholder participation with 72.69% of total outstanding shares polled.
Near-unanimous support from institutional and promoter groups, with only 2 votes cast against the resolutions.
👀 What to Watch
The near-unanimous approval indicates strong shareholder confidence in the current leadership and governance. Investors should view this as a positive sign of stability and continuity in the company's strategic direction.
Windlas Biotech Seeks Approval for Director Re-appointments and ₹1.56 Cr Annual Remuneration
Windlas Biotech has initiated a postal ballot to seek shareholder approval for the re-appointment of Mr. Ashok Kumar Windlass as Whole-time Director for a five-year term starting May 3, 2026. The proposal includes a fixed annual remuneration of ₹1.56 crore and requires a special resolution as he is over 75 years of age. Additionally, the company is seeking a second five-year term for Independent Directors Mr. Vivek Dhariwal and Mr. Gaurav Gulati. Shareholders can participate in remote e-voting from February 18 to March 19, 2026.
Key Highlights
Proposed re-appointment of Mr. Ashok Kumar Windlass as WTD for 5 years with ₹1.56 crore annual salary.
Special resolution required for Mr. Windlass to continue in office beyond the age of 75 years.
Re-appointment of two Independent Directors, Vivek Dhariwal and Gaurav Gulati, for second 5-year terms.
Remote e-voting period set for February 18, 2026, to March 19, 2026, with a cut-off date of February 13.
Aggregate remuneration of promoter executive directors may exceed SEBI Regulation 17(6)(e) limits but will remain within Section 197 ceilings.
👀 What to Watch
Investors should monitor the voting results to ensure leadership continuity and evaluate if the proposed remuneration aligns with the company's performance. No immediate portfolio changes are necessary based on this routine governance update.
Windlas Biotech Q3 Revenue Up 20% to INR 233 Cr; Plant 6 Completion Set for FY26
Windlas Biotech reported a strong Q3 FY26 with revenue growing 20% YoY to INR 233 crores, marking its 12th consecutive quarter of record revenue. The CDMO vertical led the performance with 23% growth, while the Exports segment surged 36% due to increased penetration in semi-regulated markets. Management confirmed that Plant 6 is on track for mechanical completion by the end of FY26, which will bring the total revenue capacity to approximately INR 1,100 crores. For the first 9 months of FY26, the company achieved an EPS of INR 24.02, representing a 12% YoY increase.
Key Highlights
Q3 FY26 revenue grew 20% YoY to INR 233 Cr, while 9M FY26 revenue rose 19% to INR 666 Cr.
9M FY26 EBITDA (excluding ESOP expenses) stood at INR 89 Cr with a margin of 13.3%.
Exports vertical grew 36% in Q3 FY26, significantly outperforming domestic volume growth trends.
Plant 6 mechanical completion expected by end of FY26 with an estimated capex of INR 50-60 Cr.
Total revenue capacity target set at INR 1,000 Cr for oral solids and INR 100 Cr for injectables.
👀 What to Watch
Investors should focus on the successful commissioning and utilization of Plant 6 and the injectable facility as primary growth catalysts. The company's consistent 12-quarter revenue growth streak and expansion in high-margin exports make it a strong candidate for long-term portfolios in the CDMO space.
Windlas Biotech Faces Suspension of Codeine Syrup Production; ₹55.21 Cr Revenue Impact
Windlas Biotech has received a Show Cause Notice from the Food Safety & Drug Administration (Uttarakhand), resulting in the temporary suspension of Codeine-containing cough syrup manufacturing. This specific product line contributed ₹55.21 crore to the company's total revenue in the current financial year as of February 9, 2026. While the suspension is limited to this product category, the company is preparing a detailed response to address the regulatory concerns and resume operations. Investors should monitor the duration of this suspension as it affects a material revenue stream.
Key Highlights
Temporary suspension of Codeine-containing cough syrup manufacturing by Uttarakhand authorities.
Affected product line contributed ₹55.21 crore to revenue in the current FY up to Feb 9, 2026.
Suspension is limited to Codeine-based products; other manufacturing operations remain unaffected.
Company is in the process of filing a detailed response to the Show Cause Notice within stipulated timelines.
👀 What to Watch
Investors should monitor the duration of the suspension as the affected revenue is significant. Watch for the company's formal response and any further regulatory actions or clearances from the Food Safety & Drug Administration.
